Safety record
A mixed record of favorable short-term animal observations and substantial unresolved questions — both documented honestly, no gaps hidden.
The TB-500 side effects and safety profile, as documented in the peer-reviewed literature, are a mixed record of favorable short-term animal observations and substantial unresolved questions. This page covers both — the findings where data exists, and the gaps where it does not. The domain name is honest about the site's intent: we are here to answer whether is TB-500 safe can be answered from published science, and to document clearly where it cannot.
FIG. 05 — Safety ledger overview
No systematic human adverse-event study for injectable TB-500 (Ac-LKKTETQ) exists. The following are the most frequently documented observations across available sources:
Mild redness, swelling, or discomfort at the injection site is the most consistently reported side effect across user observations and animal studies. Severity appears low in the documented reports; systemic reactions are uncommon.
Transient fatigue, mild nausea, and dizziness have been reported in anecdotal contexts. No controlled study has quantified the incidence or severity of these systemic effects for the TB-500 fragment.
The full-length Tβ4 protein (IV, 54 healthy volunteers) showed no serious adverse events and no dose-limiting toxicities.[16] This data covers the parent protein, not the TB-500 fragment, and used intravenous administration — not the subcutaneous or intramuscular route typical of research-context use.
A 2026 Sports Medicine review confirmed that rigorous human safety data for TB-500 and similar unapproved peptides are "scarce" — and that the gray market supply chain presents "potential for serious harm to patients" independent of the compound's own pharmacology.[20]
The direct answer: no human clinical trials have evaluated injectable TB-500 (Ac-LKKTETQ) safety. The compound is classified by the FDA as a Category 2 bulk drug substance — meaning it presents significant safety concerns and cannot be compounded by licensed pharmacies for human use. WADA prohibits it in competitive sport.
Animal studies show a generally favorable short-term profile at the doses studied. The Phase I data on full-length Tβ4 IV is reassuring within its narrow scope — no serious adverse events, no dose-limiting toxicities, low immunogenicity.[16] The topical ophthalmic Phase II trial similarly showed a favorable safety profile.[23]
But the question "is TB-500 safe" as applied to subcutaneous or intramuscular injectable use in humans cannot be answered from published science. Absence of reported adverse events in uncontrolled settings is not the same as demonstrated safety in a controlled trial. The honest summary: preclinical evidence is reassuring about short-term tolerability; long-term human safety is undocumented.[20]
Long-term human safety data for TB-500 does not exist. The preclinical evidence — including the 6-month dystrophic mouse study[11] and 4-week NAFLD macrophage study[22] — provides the longest available exposure data for Tβ4, and neither produced overt toxicity signals in those models. But a 6-month mouse study is not a basis for conclusions about multi-year human exposure. No multi-year human cohort study, no pharmacovigilance database, and no regulatory post-market safety record exists for injectable TB-500. The absence of reported long-term harms is not evidence of long-term safety.
The angiogenesis-and-cancer concern is documented at the same weight as the tissue repair findings — because that is what the literature supports.
— TB-500 Safe editorial approachTB-500 promotes angiogenesis via VEGF upregulation — the formation of new blood vessels. This is the proposed mechanism underlying tissue repair benefits in wound healing and cardiac models. It is also the same pathway exploited by tumors for vascularization, and this dual character is the basis of the cancer-risk concern.
Three bodies of evidence are relevant:
No human study has confirmed that exogenous TB-500 causes or promotes cancer. These are animal and in vitro data from overexpression models. However, researchers formally flag this question as unresolved. The TB-500 cancer risk cannot be dismissed as theoretical when the mechanistic pathway is this well-characterized.
The pro-angiogenic activity of TB-500 is not a theoretical risk invented by critics — it is the documented mechanism of the compound's tissue repair activity and the same documented mechanism of tumor vascularization.[12][13] Current evidence does not confirm that exogenous TB-500 promotes tumor growth in humans. Current evidence also does not rule it out.
FIG. 06 — Angiogenesis branching motif with caveat
Tβ4 has bidirectional immune-modulatory activity. It suppresses TNF-alpha-driven NF-κB activation and IL-8 expression in human cell lines[15] — an anti-inflammatory effect. It promotes macrophage M2 polarization (anti-inflammatory repair phenotype) in mouse NAFLD models.[22]
This bidirectional activity — the compound can shift immunity in either direction depending on context — underlies theoretical concerns about immune dysregulation. No human autoimmune events have been formally reported in the published literature. The Phase I Tβ4 IV study showed low immunogenicity (0.9–1.8% anti-drug antibody rate) at the doses tested.[16] Long-term immunological consequences of repeat systemic injectable use in humans are unknown.
Mild redness, swelling, or discomfort at the injection site is the most consistently reported side effect in user-reported observations and across animal studies. Severity appears low in the documented reports. Systemic reactions from injection site administration are uncommon in available data. No controlled study has systematically characterized injection site reaction incidence or severity for TB-500 in any species.
A 2023 analytical study examined internet-marketed TB500 and TB1000 products and found composition "not systematically consistent with its former descriptions."[17] The risks this creates — bacterial endotoxin contamination, incorrect peptide sequences, heavy metals, undisclosed excipients — are independent of the compound's pharmacology and represent a distinct category of safety hazard.
The FDA's Category 2 classification of TB-500 explicitly cites characterization and impurity concerns as part of its safety rationale, separate from questions about pharmacological activity. Research-grade preparations purchased outside a regulated supply chain carry contamination risks that are not measurable from the peptide literature alone.[20]